Adamis Pharmaceuticals Updates Comparative Pharmacology Model Data Supporting the Higher 5 mg Intramuscular Dose of Naloxone in ZIMHI™

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today that additional data in a quantitative systems pharmacology model supports the dose of naloxone hydrochloride that is included in the company’s ZIMHI™ (naloxone HCL Injection, USP) 5 mg/0.5 mL product.To read the press release: adamispharmaceuticals